Search

everythinglearnresearchcommunity

for

Search:↓

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

The FDA rejected a testosterone drug again due to safety concerns.

The drug combination significantly reduced epileptic drop attacks in patients.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

A cystic fibrosis patient developed Cushing's syndrome from a drug interaction between itraconazole and budesonide, which improved after stopping the medications.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.

New mutations in KRT83 and KRT86 are linked to the hair disorder monilethrix.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

The combined therapy improved symptoms in PCOS patients.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

SH-340 may improve skin barrier and help treat atopic dermatitis.

Finasteride can cause muscle pain and high creatine kinase levels, but stopping the medication may resolve symptoms.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Cadd4 effectively reduces cholesterol levels without side effects.

Bicalutamide is more effective and safer than spironolactone for treating female hair loss.

A woman experienced unusual hair loss and skin reactions after taking phenobarbital, but her hair grew back after treatment.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

New compounds show promise for treating benign prostate hyperplasia with fewer side effects.

Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.